Family · Pharmaceutical analytical standards
Neratinib
A tyrosine kinase inhibitor of HER2, EGFR and HER4, approved in the United States in 2017 and in Europe in 2018 for early-stage HER2-positive breast cancer, as extended adjuvant therapy after trastuzumab. This family brings together the active ingredient, labelled standards, nitrosamines and other impurities.
Did you know?It forms a covalent, in other words permanent, bond with a cysteine in the HER2 and EGFR receptors: this is why it stays active even against the EGFR T790M variant, which escapes non-covalent inhibitors.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
